History & Origin
About Autologous Conditioned Plasma Therapy (ACP)
ACP Therapy uses a patient's own plasma, enriched and reinjected to promote healing in injured tissues.
Autologous Conditioned Plasma Therapy emerged from the broader field of platelet-rich plasma (PRP) treatments, which began developing in the 1970s and 1980s. The concept originated from observations that platelets play a crucial role in wound healing through the release of growth factors. Early applications were primarily in oral and maxillofacial surgery, where surgeons noticed improved healing when platelet concentrates were applied to surgical sites.
The development of ACP as a specific technique can be traced to advances in blood processing technology and a growing understanding of regenerative medicine principles. In the 1990s and early 2000s, researchers and clinicians began exploring more refined methods of plasma preparation that could optimize the concentration of healing factors while minimizing unwanted inflammatory components. This led to the development of various proprietary systems for processing blood plasma.
ACP gained significant attention in orthopedic and sports medicine during the 2000s, particularly as professional athletes began using plasma-based treatments for injury recovery. The technique spread from specialized sports medicine clinics to mainstream orthopedic practice as equipment became more accessible and standardized protocols were developed.
Today, ACP represents one of several autologous blood product therapies used in regenerative medicine, with ongoing research investigating optimal preparation methods, injection techniques, and clinical applications across various medical specialties.
